PL3368555T3 - Białka o podwójnej funkcji i kompozycja farmaceutyczna je zawierająca - Google Patents

Białka o podwójnej funkcji i kompozycja farmaceutyczna je zawierająca

Info

Publication number
PL3368555T3
PL3368555T3 PL16860306.6T PL16860306T PL3368555T3 PL 3368555 T3 PL3368555 T3 PL 3368555T3 PL 16860306 T PL16860306 T PL 16860306T PL 3368555 T3 PL3368555 T3 PL 3368555T3
Authority
PL
Poland
Prior art keywords
same
pharmaceutical composition
dual function
function proteins
proteins
Prior art date
Application number
PL16860306.6T
Other languages
English (en)
Inventor
Jun Hwan Kim
Seyoung LIM
Minji Seo
Hyun Ho Choi
Dohoon Kim
Mi Kyeong Ju
Ju-Young Park
Seul Gi Kim
Sangmyoun LIM
Jong Gyun Kim
Su Youn NAM
Original Assignee
Yuhan Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corporation filed Critical Yuhan Corporation
Publication of PL3368555T3 publication Critical patent/PL3368555T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
PL16860306.6T 2015-10-28 2016-10-28 Białka o podwójnej funkcji i kompozycja farmaceutyczna je zawierająca PL3368555T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020150150576A KR102670157B1 (ko) 2015-10-28 2015-10-28 이중 작용 단백질 및 이를 포함하는 약학적 조성물
PCT/KR2016/012300 WO2017074123A1 (en) 2015-10-28 2016-10-28 Dual function proteins and pharmaceutical composition comprising same

Publications (1)

Publication Number Publication Date
PL3368555T3 true PL3368555T3 (pl) 2025-05-12

Family

ID=58630627

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16860306.6T PL3368555T3 (pl) 2015-10-28 2016-10-28 Białka o podwójnej funkcji i kompozycja farmaceutyczna je zawierająca

Country Status (21)

Country Link
US (3) US11136364B2 (pl)
EP (2) EP3368555B1 (pl)
JP (3) JP7575862B2 (pl)
KR (2) KR102670157B1 (pl)
CN (4) CN108350054B (pl)
AU (1) AU2016346870B2 (pl)
CA (1) CA3003115C (pl)
DK (1) DK3368555T3 (pl)
ES (1) ES3013110T3 (pl)
FI (1) FI3368555T3 (pl)
HR (1) HRP20250309T1 (pl)
HU (1) HUE071444T2 (pl)
LT (1) LT3368555T (pl)
MX (1) MX2018005193A (pl)
PL (1) PL3368555T3 (pl)
PT (1) PT3368555T (pl)
RS (1) RS66648B1 (pl)
RU (1) RU2741345C2 (pl)
SI (1) SI3368555T1 (pl)
WO (1) WO2017074123A1 (pl)
ZA (1) ZA201802003B (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102668200B1 (ko) * 2015-10-28 2024-05-23 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
KR102670157B1 (ko) * 2015-10-28 2024-05-29 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
CN107759697B (zh) 2016-08-19 2023-03-24 安源医药科技（上海）有限公司 制备融合蛋白的方法
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
US11123438B2 (en) 2016-08-19 2021-09-21 Ampsource Biopharma Shanghai Inc. Linker peptide for constructing fusion protein
HUE071618T2 (hu) * 2016-11-10 2025-09-28 Yuhan Corp Fúziós fehérjéket tartalmazó gyógyszerkészítmény hepatitisz, májfibrózis és májzsugor megelõzésére vagy kezelésére
WO2018166461A1 (en) 2017-03-14 2018-09-20 Sunshine Lake Pharma Co., Ltd. Dual-target fusion proteins comprising the fc portion of an immunoglobulin
CN110709520B (zh) 2017-04-21 2024-04-05 株式会社柳韩洋行 用于产生双功能蛋白质及其衍生物的方法
CN109836503B (zh) * 2017-11-24 2022-09-16 浙江道尔生物科技有限公司 一种治疗代谢疾病的多重活性蛋白
CN110028587B (zh) * 2018-01-11 2021-10-08 安源医药科技（上海）有限公司 用于调节血糖和脂质的增效型双功能蛋白
CN116098989B (zh) * 2018-02-08 2026-03-20 广东东阳光药业股份有限公司 Fgf21变体、融合蛋白及其应用
US20210275643A1 (en) * 2018-06-21 2021-09-09 Sanofi Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
WO2020071865A1 (ko) * 2018-10-04 2020-04-09 한미약품 주식회사 글루카곤 및 이를 포함하는 조합물의 치료학적 용도
CN109836486B (zh) * 2019-01-30 2020-09-08 北京双因生物科技有限公司 成纤维生长因子21变体、其融合蛋白及其用途
AU2020230668B2 (en) 2019-03-05 2025-05-29 Sunshine Lake Pharma Co., Ltd. A polypeptide molecule and application thereof
CN114853908B (zh) * 2019-05-16 2024-06-07 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
IL324962A (en) 2019-11-27 2026-01-01 Gi Innovation Inc Pharmaceutical preparation for the treatment of cancer containing a fusion protein containing 2-il protein and 80cd protein and an immune checkpoint inhibitor
WO2021136223A1 (en) 2019-12-31 2021-07-08 Beijing Ql Biopharmaceutical Co., Ltd. Fusion proteins of glp-1 and gdf15 and conjugates thereof
CN113366024B (zh) * 2020-01-08 2024-11-05 上海翰森生物医药科技有限公司 Fgf21突变体蛋白及其融合蛋白
CN113728013B (zh) 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
WO2022002409A1 (en) * 2020-07-02 2022-01-06 Sanofi Glp-1r agonistic peptides with reduced activity
US20230265152A1 (en) * 2020-07-02 2023-08-24 Sanofi Glp-1r agonist / fgf21 fusion proteins
US20240165202A1 (en) * 2021-03-19 2024-05-23 Sunshine Lake Pharma Co., Ltd. Uses of fgf21 polypeptides and fusion polypeptides thereof
CN113265007B (zh) * 2021-06-10 2022-02-15 江南大学 一种治疗代谢疾病的融合蛋白及其制备方法和应用
WO2023284822A1 (en) 2021-07-14 2023-01-19 Beijing Ql Biopharmaceutical Co., Ltd. Fusion polypeptides for metabolic disorders
CN117510646A (zh) * 2022-08-03 2024-02-06 无锡市华盛康肽生物技术有限公司 一种双功能融合蛋白及其用途
AU2023337288A1 (en) * 2022-09-08 2025-03-13 Gmax Biopharm Llc Gipr antibody, fusion protein thereof with fgf21, pharmaceutical composition thereof, and use thereof
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
KR20250124360A (ko) 2023-01-30 2025-08-19 닛폰세이테츠 가부시키가이샤 테일러드 블랭크, 프레스 성형품, 테일러드 블랭크의 제조 방법, 및 프레스 성형품의 제조 방법
CN117143242B (zh) * 2023-10-30 2024-03-29 南京佰抗生物科技有限公司 抗Galectin-3蛋白的单克隆抗体组合物及应用
CN117942425B (zh) * 2024-03-27 2024-10-22 杭州惠康医疗器械有限公司 一种促进伤口愈合的水凝胶敷料及其制备方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
WO1990002175A1 (en) 1988-08-16 1990-03-08 Novo Nordisk A/S A method of producing polypeptides by culturing eukaryotic cells in the presence of protease inhibitors
US5851800A (en) 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
WO2003011213A2 (en) 2001-07-30 2003-02-13 Eli Lilly And Company Method for treating diabetes and obesity
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
ES2371072T3 (es) 2003-06-12 2011-12-27 Eli Lilly And Company Proteínas de fusión análogas de glp-1.
WO2005091944A2 (en) 2004-03-17 2005-10-06 Eli Lilly And Company Glycol linked fgf-21 compounds
AU2007240315A1 (en) * 2006-04-20 2007-11-01 Amgen Inc. GLP-1 compound/glucagon antibody compositions
CA2679107C (en) 2007-02-23 2018-01-16 Sk Chemicals Co., Ltd. Process for producing and purifying factor viii and its derivatives
US20110034373A1 (en) * 2007-08-03 2011-02-10 Eli Lilly And Company Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
SG193860A1 (en) * 2008-06-04 2013-10-30 Amgen Inc Fgf21 mutants and uses thereof
WO2010065439A1 (en) 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
WO2011089170A2 (en) 2010-01-22 2011-07-28 Novo Nordisk A/S Process for preparing fgf-21 with low degree of o-glycosylation
CN102361647B (zh) * 2009-01-23 2018-02-16 诺沃-诺迪斯克有限公司 具有白蛋白结合剂a‑b‑c‑d‑e‑的fgf21衍生物及其应用
DK3178835T3 (da) 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
BRPI1011404B1 (pt) * 2009-05-05 2022-05-03 Amgen Inc Polipeptídeos mutantes fgf21, polipeptídeo de fusão, multímero, composição farmacêutica, ácido nucleico isolado, vetor e célula hospedeira
AU2010246038A1 (en) * 2009-05-05 2011-12-01 Amgen Inc. FGF21 mutants and uses thereof
CN102802657A (zh) * 2009-06-11 2012-11-28 诺沃-诺迪斯克有限公司 用于治疗2型糖尿病的glp-1和fgf21组合
CN101993485B (zh) 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
CN101993496B (zh) * 2009-08-20 2013-06-05 重庆富进生物医药有限公司 双重调节血糖血脂融合蛋白及其制法和用途
CN103415300B (zh) 2010-07-20 2018-02-23 诺沃—诺迪斯克有限公司 N‑末端修饰的fgf21化合物
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
US9574002B2 (en) 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
EP2548570A1 (en) 2011-07-19 2013-01-23 Sanofi Pharmaceutical composition for treating a metabolic syndrome
WO2013033452A2 (en) 2011-08-31 2013-03-07 Amgen Inc. Method of treating or ameliorating type 1 diabetes using fgf21
US9458214B2 (en) * 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
JO3476B1 (ar) * 2011-09-26 2020-07-05 Novartis Ag بروتينات مندمجة لعلاج الاضطرابات الايضية
CN102558358A (zh) 2011-12-30 2012-07-11 张海涛 人成纤维细胞生长因子21融合蛋白及其突变体的制备与应用
WO2013131091A1 (en) * 2012-03-02 2013-09-06 New York University Chimeric fgf21 proteins with enhanced binding affinity for beta-klotho for the treatment of type ii diabetes, obesity and related metabolic disorders
TWI513705B (zh) 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質
AR092076A1 (es) * 2012-08-22 2015-03-18 Lilly Co Eli Proteinas homodimericas
MX2015002985A (es) * 2012-09-07 2015-06-22 Sanofi Sa Proteinas de fusion para el tratamiento de un sindrome metabolico.
WO2014130659A1 (en) 2013-02-22 2014-08-28 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
WO2015038938A1 (en) * 2013-09-13 2015-03-19 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
MX2017004947A (es) 2014-10-24 2017-06-29 Bristol Myers Squibb Co Polipeptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos.
KR102670157B1 (ko) * 2015-10-28 2024-05-29 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
KR102668200B1 (ko) * 2015-10-28 2024-05-23 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
CN105288592A (zh) 2015-11-02 2016-02-03 哈尔滨博翱生物医药技术开发有限公司 成纤维细胞生长因子-21成熟肽在制备肝纤维化治疗药物中的应用
WO2018166461A1 (en) 2017-03-14 2018-09-20 Sunshine Lake Pharma Co., Ltd. Dual-target fusion proteins comprising the fc portion of an immunoglobulin
CN110709520B (zh) 2017-04-21 2024-04-05 株式会社柳韩洋行 用于产生双功能蛋白质及其衍生物的方法

Also Published As

Publication number Publication date
HK1257373A1 (zh) 2019-10-18
ZA201802003B (en) 2019-05-29
CN108350054B (zh) 2022-09-02
CN116333160A (zh) 2023-06-27
ES3013110T3 (en) 2025-04-11
KR102927838B1 (ko) 2026-02-20
CA3003115A1 (en) 2017-05-04
EP4527403A3 (en) 2025-09-24
EP4527403A2 (en) 2025-03-26
AU2016346870B2 (en) 2021-04-22
PT3368555T (pt) 2025-02-28
EP3368555A1 (en) 2018-09-05
LT3368555T (lt) 2025-04-10
JP2023011644A (ja) 2023-01-24
CN115925978A (zh) 2023-04-07
CN115925979A (zh) 2023-04-07
NZ741439A (en) 2025-02-28
US20250270269A1 (en) 2025-08-28
US20220002368A1 (en) 2022-01-06
CN108350054A (zh) 2018-07-31
WO2017074123A1 (en) 2017-05-04
RU2018118025A3 (pl) 2020-03-24
JP2019500013A (ja) 2019-01-10
RU2741345C2 (ru) 2021-01-25
CA3003115C (en) 2025-05-27
HRP20250309T1 (hr) 2025-04-25
JP7575862B2 (ja) 2024-10-30
MX2018005193A (es) 2018-07-06
DK3368555T3 (da) 2025-04-14
KR20170049320A (ko) 2017-05-10
KR20240078629A (ko) 2024-06-04
SI3368555T1 (sl) 2025-05-30
BR112018008805A8 (pt) 2019-02-26
EP3368555B1 (en) 2025-01-15
HUE071444T2 (hu) 2025-09-28
AU2016346870A1 (en) 2018-05-10
RU2018118025A (ru) 2019-11-28
US11136364B2 (en) 2021-10-05
KR102670157B1 (ko) 2024-05-29
BR112018008805A2 (en) 2018-10-30
FI3368555T3 (fi) 2025-02-25
RS66648B1 (sr) 2025-04-30
US20200024318A1 (en) 2020-01-23
JP2025128179A (ja) 2025-09-02
EP3368555A4 (en) 2019-11-20

Similar Documents

Publication Publication Date Title
ZA201802003B (en) Dual function proteins and pharmaceutical composition comprising same
ZA201802125B (en) Pharmaceutical composition and application thereof
IL269061A (en) A pharmaceutical preparation containing Selexifag
EP3347472A4 (en) COMPOSITIONS WITH CYP76AD1 CLADE POLYPEPTIDES AND USES THEREOF
PT3603620T (pt) Composição lipossomal e composição farmacêutica
IL253538A0 (en) Heterocyclic compound and pharmaceutical compound containing it
EP3307265A4 (en) Pharmaceutical combination and uses thereof
IL255293A0 (en) A protein that binds to rgma and its use
PL3233111T3 (pl) Kompozycja farmaceutyczna zawierająca plazminogen i jej zastosowania
IL262929B1 (en) Preparations for treatment, methods of their preparation and their uses
EP3388085A4 (en) PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF
IL263040A (en) Pharmaceutical composition comprising eteplirsen
GB2546439B (en) Ezrin-derived peptides and pharmaceutical compositions thereof
IL260321B (en) A multi-antigenic structure and a pharmaceutical preparation containing it
EP3399990A4 (en) THERAPEUTIC COMPOSITIONS WITH PEPTIDES AND USES THEREOF
SMT202000281T1 (it) Composizioni farmaceutiche e loro uso
EP3325499A4 (en) Novel peptide and use thereof
GB201519644D0 (en) Therapy and pharmaceutical composition
EP3272360A4 (en) Pharmaceutical composition comprising polypeptide
PL3424500T3 (pl) Kompozycja farmaceutyczna zawierająca famitynib
HK1237802B (en) Ezrin-derived peptides and pharmaceutical compositions thereof
HK1237802A1 (en) Ezrin-derived peptides and pharmaceutical compositions thereof
AU2015902260A0 (en) Pharmaceutical Combination and Uses Thereof
AU2015901459A0 (en) Pharmaceutical powder composition and use